Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Bersiporocin with Nebivolol or Paroxetine in Healthy Volunteers
NCT04888728Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jun 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bersiporocin in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration (Cmax) of Nebivolol at Day 8, Area Under the Concentration-Time Curve (AUCt) of Nebivolol at Day 8 and 2 more. Started Jun 2021; status: completed.
02
Drugs
bersiporocin
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04888728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04888728.